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Abstract
Background: The Notch signaling pathway is an evolutionary conserved signal transduction pathway involved in embryonic
patterning and regulation of cell fates during development and self-renewal. Recent studies have demonstrated that this
pathway is integral to a complex system of interactions, involving as well other signal transduction pathways, and
implicated in distinct human diseases. Delta-like 1 (Dll1) is one of the known ligands of the Notch receptors. The role of the
Notch ligands is less well understood. Loss-of-function of Dll1 leads to embryonic lethality, but reduction of Delta-like 1
protein levels has not been studied in adult stage.
Methodology/Principal Findings: Here we present the haploinsufficient phenotype of Dll1 and a missense mutant Dll1
allele (Dll1
C413Y). Haploinsufficiency leads to a complex phenotype with several biological processes altered. These
alterations reveal the importance of Dll1 mainly in metabolism, energy balance and in immunology. The animals are smaller,
lighter, with altered fat to lean ratio and have increased blood pressure and a slight bradycardia. The animals have reduced
cholesterol and triglyceride levels in blood. At the immunological level a subtle phenotype is observed due to the effect and
fine-tuning of the signaling network at the different levels of differentiation, proliferation and function of lymphocytes.
Moreover, the importance of the proteolytic regulation of the Notch signaling network emphasized.
Conclusions/Significance: In conclusion, slight alterations in one player of Notch signaling alter the entire organism,
emphasizing the fine-tuning character of this pathway in a high number of processes.
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Introduction
The Notch signaling pathway is an intercellular signaling
mechanism that is highly conserved during evolution of verte-
brates. It is involved in the determination of cell fates in different
cell types during embryonic development. First described in the
fly, Notch orthologs have been identified successively in many
species including birds, rodents and man. In mammals four
distinct Notch genes (Notch1–Notch4) have been identified. The
Notch receptors are anchored to the membrane via a single
transmembrane domain. Two families of transmembrane ligands
interact with the Notch receptors, the Delta and the Jagged/
Serrate proteins. In mammals three Delta and two Jagged/Serrate
class proteins have been described. The canonical Notch signaling
pathway involves proteolytic processing events that cleave the
Notch receptors in response to ligand activation, leading to the
activation of target genes (frequently basic helix-loop-helix
transcriptional factors) (for review see [1–3]).
Loss- or gain-of-function of the Notch receptors or their ligands
have diverse and often severe clinical, physiological and biological
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lymphoblastic leukemia, aortic valve disease, and familial forms of
cardiomyopathy, have been associated with mutations in Notch1.
Alagille syndrome, a developmental disease, is associated with
mutations in Jagged1 and in less extent with mutations in Notch2.
Mutations in Notch3 lead to a neurological disease, a cerebral
arteriopathy autosomal dominant disease with subcortical infarcts
and leukoencephalopathy abbreviated as CADASIL. Mutations in
Delta3 have been associated with spondylocostal dysostosis which
leads to severe congenital malformations of the vertebral column.
Notch signaling and associated disease involve not only these
inherited disorders. Recent publications revealed the involvement
of Notch signaling in tumor associated angiogenesis (for review see
[6,7]). Experiments in animal models show that the Notch
signaling pathway also plays an important role in tissue
regeneration after injury of adult organs, such as heart, liver,
brain, kidney and pancreas [8–12]. Therefore, Notch signaling has
many diverse roles in physiology and pathology.
The fine-tuning of this complex system of regulatory interac-
tions with pleiotropic functions is essential to avoid disease states,
but not yet fully understood. One efficient approach to identify
components of a molecular network is to perform genetic modifier-
or sensitized-screens [13]. Recently, we reported the identification
of phenotypic modifiers in a sensitized screen using Dll1
heterozygous (Dll1
tm1Gos/+) animals [14]. A complementary
approach to better understand pleiotropic Notch signaling
functions is to investigate the haploinsufficient phenotype of Notch
pathway members, since most homozygous Notch mutants and
mutant alleles of interacting proteins or ligands are embryonic
lethal [15–19]. Here, we have comprehensively analyzed the
phenotype of Dll1
tm1Gos heterozygous animals and of a missense
mutant Dll1 allele (Dll1
C413Y) in 14 phenotyping platforms
covering more than 350 parameters at the German Mouse Clinic
(GMC) [20–22].
Haploinsufficiency was recently investigated for the Notch
ligand Jagged1 in two inbred mouse strains with distinct
phenotypes [23], so the genetic background of the inbred mouse
strain may affect the observable mutant phenotype. We present
here the haploinsufficient phenotype of Dll1
tm1Gos/+ mice on the
C3HeB/FeJ genetic background and compare the results to
previously recorded data on the 129X1/SvJ genetic background.
Results
Genetic background of Dll1
tm1Gos/+ mice
We outcrossed the mice carrying the Dll1
tm1Gos allele [15] from a
129X1/SvJ (129X1) genetic background for 11 generations to the
C3HeB/FeJ (C3H) genetic background. The 129X1 genetic
background was recently identified as being non-isogenic [14].
In the C3.Dll1
tm1Gos/+ animals only one of 137 genome-wide SNPs
showed heterozygosity (data not shown). This SNP (rs13482869) is
at a distance of approximately 5 Mb to the Dll1 gene in which the
lacZ reporter gene was inserted to disrupt the Dll1 coding sequence
[15].
Body weight, size and body composition
C3.Dll1
tm1Gos/+ animals are significantly lighter than wild-type
littermates (Figure 1A). This difference in body weight is more
pronounced in C3H than in 129X1 and mixed (129X1/
SvJ.C57BL6/J) genetic backgrounds [14]. Heterozygous C3H
females showed on average an 18% to 20% reduction and
heterozygous C3H males on average an 11% to 15% reduction in
their body weight at 15 weeks after birth (depending on the
analyzed cohort, see Figure 1A and Table S1). The average body
weights of C3.Dll1
tm1Gos/+ mice were also reduced at 6, 8, 10, and
12 weeks of age (Table S1).
Male and female Dll1
tm1Gos/+ animals were significantly shorter
than their wild-type littermates (Figure 1B). To investigate body
composition a cohort of mutant and wild-type 129X1 mice
entered the metabolic screen at 30 to 32 weeks of age. No
significant differences in the water contents of wild-type and
Dll1
tm1Gos/+ animals could be detected (data not shown). Using the
Soxhlet lipid extraction with petrol ether as solvent the body fat,
fat-free dry mass, and lean-body mass of the mice were measured.
129.Dll1
tm1Gos/+ animals showed a significantly reduced average
body fat content (Figure 1C), reduced average fat-free dry mass
(Figure 1D) and a reduced average lean-body mass (Figure 1E)
when compared to wild-type littermates. Importantly, the average
fat to lean mass ratio was significantly reduced in male and slightly
reduced in female heterozygous mutants when compared to wild-
type animals (Figure 1F). Similarly, C3.Dll1
tm1Gos/+ animals showed
reduced body fat and lean mass based upon DEXA densitometry
(see Table S1).
In summary, Dll1
tm1Gos/+ animals are shorter; show a reduced
body weight and an altered body composition, independently from
the two genetic backgrounds.
Energy metabolism
C3.Dll1
tm1Gos/+ animals on average consumed significantly less
food ad libitum and had a reduced energy uptake as compared to
wild-type littermates (Figure 2A). However, when energy uptake
was normalized to body weight only the male Dll1
tm1Gos/+ mice
showed a significant increase of energy uptake in comparison to
wild-type males. No such difference in body weight normalized
energy uptake was observed between wild-type and C3.Dll1
tm1Gos/+
females (Figure 2B).
As a consequence of decreased food intake, both male and
female C3.Dll1
tm1Gos/+ animals showed significantly reduced feces
excretion per day compared to wild-type littermates (Figure 2C).
The metabolized energy of individual mice was measured by
subtracting the energy content of collected feces and urine from
the energy uptake. Both female and male C3.Dll1
tm1Gos/+ mice
showed significantly reduced metabolized energy (Figure 2D).
When normalized to the individual body weights, significantly
increased metabolized energy was detected only for the group of
C3.Dll1
tm1Gos/+ males (Figure 2E). In contrast, in 129.Dll1
tm1Gos/+
mice only females showed increased energy uptake and metabo-
lized energy compared to wild-type female littermates. The
tendency towards this difference in both parameters was also
evident for male 129.Dll1
tm1Gos/+ mice (see Table S2).
To further analyze the differences in metabolized energy, mice
of both genetic strains were fasted for two days. Heterozygous
animals of both sexes and genetic backgrounds showed a greater
loss of body weight than the corresponding controls. This
difference was statistically significant for male C3.Dll1
tm1Gos/+ and
female 129.Dll1
tm1Gos/+ mice (Figure 2F and Table S2).
In conclusion, our data suggest that Dll1 heterozygosity causes
increased energy requirements.
The cardiovascular mutant phenotype
At the age of 14 weeks C3.Dll1
tm1Gos/+ and wild-type littermates
were analyzed for cardiovascular parameters. The systolic,
diastolic and mean arterial pressures were significantly elevated
in C3.Dll1
tm1Gos/+ male mice (Figure 3A–C). The resting heart rate
was determined during blood pressure measurements (‘‘pulse’’ in
beats per minute, bpm) and in anaesthetized mice during
electrocardiography (‘‘heart rate’’ in bpm). In C3.Dll1
tm1Gos/+
female animals the average pulse was significantly, in male mice
Dll1 Haploinsufficiency
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tm1Gos/+ animals compared to wild-type littermates. A–B) Body
weight and body length were determined at 15 and 16 weeks of age, respectively, in two different cohorts. Depicted are the scatter dot plot
representations and the mean for each group: heterozygous C3.Dll1
tm1Gos/+ males (weight, n=13; length, n=9) and their wild-type littermates
(C3.Dll1
+/+, weight, n=15; length, n=10) and heterozygous C3.Dll1
tm1Gos/+ females (n=10) and their wild-type littermates (C3.Dll1
+/+, weight, n=10;
length, n=9). C–F) Selected metabolic parameters were recorded using the Soxhlet lipid extraction with petrol ether as solvent in the tertiary screen
at the GMC at 30–32 weeks of age. Depicted are the scatter dot plot representations for and the mean for each group: heterozygous 129.Dll1
tm1Gos/+
males (n=13) and their wild-type littermates (C3.Dll1
+/+, n=14); heterozygous C3.Dll1
tm1Gos/+ females (n=14) and their wild-type littermates
(129.Dll1
+/+, n=15). P-value calculated performing unpaired t-test when variances were not significantly different. If significantly different then the
Mann-Whitney test was performed. P-value: * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0006054.g001
Figure 2. Metabolic parameters collected from heterozygous C3.Dll1
tm1Gos/+ animals and their wild-type littermates at the GMC. A–E)
Values were recorded during 2 weeks ad libitum feeding. F) Body weight decrease (%) after two days fasting. Depicted are the scatter dot plot
representations and the mean for each group: heterozygous C3.Dll1
tm1Gos/+ males (n=7) and their wild-type littermates (C3.Dll1
+/+, n=7);
heterozygous C3.Dll1
tm1Gos/+ females (n=6) and their wild-type littermates (C3.Dll1
+/+, n=7). P-value calculated performing unpaired t-test when
variances were not significantly different. If significantly different then the Mann-Whitney test was performed. P-value: * P,0.05, ** P,0.01, ***
P,0.001.
doi:10.1371/journal.pone.0006054.g002
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The heart rate was significantly decreased in both male and female
C3.Dll1
tm1Gos/+ animals (Figure 3E), indicating a slight bradycardia
in heterozygous mutant animals. Moreover, the Q amplitude was
significantly increased in the electrocardiogram traces of hetero-
zygotes (Figure 3F).
Alteration of clinical chemical blood parameters
At 12 weeks of age blood samples were taken from fed mice for
the analysis of 20 clinical chemical parameters (see Table S3). The
concentrations of total protein, uric acid, triglycerides and
transferrin, as well as a-amylase activity were significantly
decreased in male and female C3.Dll1
tm1Gos/+ animals (Figure 4A–
E). In addition, several other blood parameters were significantly
altered in heterozygous mutant mice of only one gender (see Table
S3). For example, the average concentration of cholesterol in the
blood of C3.Dll1
tm1Gos/+ mice was significantly reduced only in
male animals (Figure 4F). Taken together, our data demonstrate
that heterozygosity for a Dll1 loss-of-function allele resulted in
altered blood concentrations of key metabolites of the protein,
carbohydrate and fat metabolism.
Immunology screen
The same blood samples as above were analyzed by flow
cytometry and indirect ELISA. The population of CD19 positive
cells (B-cell population) was significantly increased in female but
not male Dll1
tm1Gos/+ animals of both genetic backgrounds
compared to corresponding wild-type littermates (Table 1 and
data not shown). Moreover, the proportion of B1 cells within the B
cluster was significantly decreased in female C3.Dll1
tm1Gos/+ mice.
A reduction of the CD4
+ T-cell population in C3.Dll1
tm1Gos/+ mice
was significant only in females (Table 1). A similar reduction in
CD4
+ cells was observed in the 129.Dll1
tm1Gos/+ genetic back-
ground, although the difference between wild-type mice and
heterozygous mutants was not statistically significant (data not
shown). The population of CD8a,b T-cells showed sex-dependent
differences. Compared to the results for the corresponding wild-
type littermates this cell population was significantly increased in
male and significantly decreased in female heterozygous mutant
animals (Table 1). IgG1, IgG2b, IgG3 and IgA parameters were
significantly decreased in female C3.Dll1
tm1Gos/+ animals. In
conclusion, our data suggest that haploinsufficiency of Dll1 causes
alterations in immunological parameters, in particular in the
number of B-lymphocytes.
Dysmorphology screen
At the age of 9 weeks wild-type and C3.Dll1
tm1Gos/+ mice were
analyzed for 26 dysmorphology parameters (see Materials and
Methods). One wild-type animal out of 58 showed a variant
phenotype (kinked tail phenotype), whereas their heterozygous
C3.Dll1
tm1Gos/+ littermates showed seven variant phenotypes (3
small-body size and 4 kinked tail phenotypes, see Table 2). The
Fisher’s exact test revealed no significant differences between
heterozygous C3.Dll1
tm1Gos/+ and wild-type animals in the appear-
ance of a variant morphological phenotype. The reduced body
weight and body length of Dll1
tm1Gos/+ mice were described above.
At 16 to 17 weeks of age 9 to 10 animals of each group
(separated by genotype and gender) were investigated with X-ray
Figure 3. Selected blood pressure and electrocardiogram parameters in heterozygous C3.Dll1
tm1Gos/+ animals and their wild-type
littermates. A–F) Depicted are the scatter dot plot representations and the mean for each group: heterozygous C3.Dll1
tm1Gos/+ males (n=10) and
their wild-type littermates (C3.Dll1
+/+, n=10); heterozygous C3.Dll1
tm1Gos/+ females (n=10) and their wild-type littermates (C3.Dll1
+/+, n=9). P-value
calculated performing unpaired t-test as variances were not significantly different. P-value: * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0006054.g003
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tm1Gos/+ animal
showed a reduced number of lumbar vertebrae (Table 2). No
differences were observed in other parts of the axial skeleton. In
the 129X1 background, a different number of lumbar vertebrae
was found in heterozygous and wild-type animals. The Fisher’s
Exact test revealed no significant differences due to the genotype
and appearance of an abnormal number of lumbar vertebrae.
Further bone parameters were measured using DEXA densi-
tometry. Whole body bone mineral density (BMD) was signifi-
cantly reduced in the C3.Dll1
tm1Gos/+ animals compared to their
wild-type littermates (Figure 5A). Nevertheless, when related to
body weight the specific bone mineral density (sBMD) was
significantly increased in C3.Dll1
tm1Gos/+ animals (Figure 5B).
Whole body bone mineral content (BMC) was significantly
reduced in C3.Dll1
tm1Gos/+ females, and a similar tendency was
observed in male animals (Figure 5C). No differences were found
when the bone content was related to body weight (Figure 5D).
Comparable results were found for heterozygous mutant and
wild-type mice of the 129X1 background (data not shown).
Changes in gene expression patterns
A set of 11 organs from 5 wild-type and 5 heterozygous
C3.Dll1
tm1Gos/+ male animals was archived for subsequent
expression profiling analysis [24]. The brain was selected for the
analysis because Dll1 plays an important role in the differentiation
of neuronal precursors [25]. Spleen and thymus were chosen
based on the requirement of Dll1 signaling for immunological
parameters [26,27]. Finally, gene expression in liver was studied
due to the importance of the organ in overall energy metabolism.
In brain and spleen no significantly regulated genes were detected.
13 significantly downregulated genes were found in the liver
of C3.Dll1
tm1Gos/+ animals (Table 3). No up-regulated genes
were identified in this organ. Among the regulated genes several
are associated with metabolic liver functions, like cholesterol
biosynthesis.
In the thymus of heterozygous mutant animals no up-regulated
genes were detected. Instead, 15 genes were significantly
downregulated in heterozygous C3.Dll1
tm1Gos1/+ animals (Table 3).
One third are associated with T cell differentiation or involved in
the progress of maturation or migration of T cells and several have
unknown functions. Some of the genes regulated in the thymus of
heterozygous mutant animals were also found to be regulated in
homozygous mutant embryos such as Ddx6, Higd1b and polypep-
tides of Ywha (14-3-3) complex ([28] and unpublished data).
Variant phenotype of the missense mutant line
C3.Dll1
C413Y/+
The C3.Dll1
C413Y/+ mutant line was isolated from an ENU
mutagenized combined sperm and genome archive by sequencing
the Dll1 coding region [29]. C3.Dll1
C413Y/+ mutants have a
missense mutation in exon 8 which leads to the exchange of the
cysteine in position 413 by a tyrosine. This mutation lies within the
predicted 6
th EGF-like repeat, which is highly conserved from
insects to vertebrates (Figure 6).
Unlike homozygous Dll1
tm1Gos mutants, homozygous
C3.Dll1
C413Y/C413Y mutants are viable, although only 32% of
the expected homozygous animals are alive after weaning.
Dll1
C413Y/C413Y animals are lighter than their wild-type and
heterozygous littermates and are generally in a bad health
condition. Most of them died or had to be sacrificed within the
first months of life. Since we suspect that the Dll1
C413Y mutation is
a partial loss-of-function, we compared the phenotype of
Dll1
C413Y/+ with Dll1
tm1Gos/+ animals (Table 4). Several phenotypes
of Dll1
tm1Gos/+ mice were also found in Dll1
C413Y/+ mice. For
Figure 4. Selected clinical chemistry parameters in heterozygous C3.Dll1
tm1Gos animals and their wild-type littermates. A–F) Depicted
are the scatter dot plot representations and the mean for each group: heterozygous C3.Dll1
tm1Gos/+ males (n=15) and their wild-type littermates
(C3.Dll1
+/+, n=14) and heterozygous C3.Dll1
tm1Gos/+ females (n=14) and their wild-type littermates (C3.Dll1
+/+, n=15). P-value calculated performing
unpaired t-test when variances were not significantly different. If significantly different then the Mann-Whitney test was performed. P-value: * P,0.05,
** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0006054.g004
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tm1Gos/+ animals.
Sex Parameter C3.Dll1
+/+ C3.Dll1
tm1Gos/+ P-value Regulation
Male CD19
+ (%) 13.0061.63 12.9862.60 0.98 «
Cd19
+/CD5
2 (%) 86.3362.16 88.0361.22 0.044* q
Cd19
+/CD5
+ (%) 13.6962.17 11.9861.21 0.043* Q
CD8a
+ (%) 11.6760.66 10.7861.27 0.066 «
CD4
+ (%) 27.3763.36 25.2962.34 0.13 «
CD8a/b
+ (%) 9.3660.92 10.6761.49 0.036* q
Gr-1
+ (%) 8.7362.17 8.9661.97 0.81 «
c/d TCR
+ (%) 0.4060.20 0.4860.21 0.44 «
IgG1 (mg/ml) 60.64630.94 82.45632.25 0.085 «
IgG2a (mg/ml) 219.086151.26 217.376147.51 0.98 «
IgG2b (mg/ml) 78.59620.35 83.78633.45 0.61 «
IgG3 (mg/ml) 195.84688.51 180.41668.46 0.60 «
IgA (mg/ml) 320.316190.92 333.296222.32 0.87 «
Anti-DNA (%) 0.4060.03 0.3960.04 0.56 «
Rheumatoid. factor (%) 0.1760.02 0.1660.02 0.51 «
Female CD19
+ (%) 13.7063.57 20.2863.32 0.00065*** q
Cd19
+/CD5
2 (%) 77.8467.89 82.1362.32 0.15 «
Cd19
+/CD5
+ (%) 22.1667.89 17.8762.32 0.15 «
CD8a
+ (%) 10.2661.14 9.6461.71 0.37 «
CD4
+ (%) 31.5364.27 22.6063.49 0.00011*** Q
CD8a/b
+ (%) 10.2261.12 8.5361.09 0.0040** Q
Gr-1
+ (%) 8.6061.96 7.8662.17 0.43 «
c/d TCR
+ (%) 0.0560.02 0.0560.02 0.60 «
IgG1 (mg/ml) 136.10653.21 72.61636.40 0.00092*** Q
IgG2a (mg/ml) 331.726222.39 224.286138.18 0.16 «
IgG2b (mg/ml) 152.65669.31 94.36658.59 0.022* Q
IgG3 (mg/ml) 302.336134.89 160.71680.02 0.0021*** Q
IgA (mg/ml) 377.326132.22 218.626164.50 0.014* Q
Anti-DNA (%) 0.5160.08 0.4460.05 0.0099** Q
Rheumatoid. factor (%) 0.2260.07 0.1860.01 0.07 «
Values displayed as mean6SD. Data obtained by flow cytometry and indirect ELISA. P-value calculated performing unpaired t-test with samples with equal variances, if
not Mann-Whitney test performed: *,0.05, **,0.01, ***,0.001.
doi:10.1371/journal.pone.0006054.t001
Table 2. Skeletal phenotyping of heterozygous Dll1
tm1Gos/+ animals.
Phenotyping screen Genotype No variation Variation Two-sided P-value
Dysmorphology C3.Dll1
+/+ 58 1* 0.061
C3.Dll1
tm1Gos/+ 52 7
Quantification lumbar vertebrae C3.Dll1
+/+ 19 0 0.678
C3.Dll1
tm1Gos/+ 19 1
129.Dll1
+/+ 17 2
129.Dll1
tm1Gos/+ 16 3
Displayed are the numbers of animals showing the observed phenotypes.
*One animal was removed of the analysis, as its variant phenotype, an abnormal eye, could be rather due to injury than a genetic component.
The two-sided P-value was calculated using the Fisher’s Exact Test or the Chi-square for the genome-wide vs modifier screen, due to the higher number of cases
compared.
P-value: *,0.05, **,0.01, ***,0.001.
doi:10.1371/journal.pone.0006054.t002
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C3.Dll1
C413Y/+ animals was decreased comparable to
C3.Dll1
tm1Gos/+ mice. In addition, the C3.Dll1
C413Y/+ animals show
a significantly reduced bone mass density and bone mineral
content. The fat mass was also significantly decreased in
C3.Dll1
C413Y/+ animals. Also comparable to the changes observed
in Dll1
tm1Gos/+ animals, the systolic, diastolic and mean arterial
pressures were significantly increased, and the pulse significantly
decreased in C3.Dll1
C413Y/+ animals. However, lean mass,
locomotor activity, and metabolized energy were increased in
Dll1
C413Y/+ compared to wild-type littermates. This is somewhat in
contrast to Dll1
tm1Gos/+ animals, which showed a significant
decrease in lean mass and a tendency towards reduced locomotor
activity. Concerning the clinical chemical parameters both mutant
lines showed similar tendencies in the concentrations of cholesterol
and triglycerides in their blood plasma. Whereas Dll1
tm1Gos/+
animals showed decreased concentrations of urea, this concentra-
tion was significantly increased in the blood of Dll1
C413Y/+ animals.
Finally, in contrast to the Dll1
tm1Gos/+, no differences were observed
in populations of CD19+ and CD4+ cell lines between the
C3.Dll1
C413Y/+ and wild-type littermates.
Discussion
The comprehensive investigation of Dll1 haploinsufficiency
reveals a complex phenotype, indicating that several biological
processes are affected.
Immunological phenotype
One of the most studied roles of Notch signaling in adult stages
is its involvement in T/B-cell commitment (for review see [26,27]).
Despite a high number of studies, all mechanisms in this process
still have not been elucidated. In particular, the role of the Notch
ligands is less understood.
Hematopoietic stem cells of the bone marrow give rise to CLP,
further proB cells, and immature B cells (in the case that Notch1 is
inactive). These cells migrate to the spleen where differentiation
occurs. Although we did not detect any differentially regulated gene
in the spleen, the frequencies of B- and T-cell populations in the
blood of heterozygous animals showa sex-dependent phenotype. As
in wild-type mice of different strains under baseline conditions the
frequency of T cells is generally higher in females [30], we could
interpret our findings as a loss of sex-difference in the size of the
Figure 5. Selected bone parameters obtained with a Dual energy X-ray absorptiometer from heterozygous C3.Dll1
tm1Gos/+animals.
A–D) Depicted are the scatter dot plot representations and the mean for each group: heterozygous C3.Dll1
tm1Gos/+ males (n=10) and their wild-type
littermates (C3.Dll1
+/+, n=10); heterozygous C3.Dll1
tm1Gos/+ females (n=9) and their wild-type littermates (C3.Dll1
+/+, n=10). P-values calculated
performing unpaired t-test when variances were not significantly different. If significantly different then the Mann-Whitney test was performed.
P-value: * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0006054.g005
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sex-dependent regulatory mechanisms remains unclear.
Hozumi et al. [31] previously demonstrated that conditional
ablation of Dll1 in hematopoietic cells leads to a disappearance of
the marginal zone in the spleen. In the spleen, type 1 transitional
B-cells (B1) differentiate into follicular and marginal zone cells.
Although not directly investigated, our data affirm the role of
Delta-like 1 in B cell commitment and maturation.
The CD8ab
+ T cell blood profile of the mutant Dll1 looks
ambiguous. CD8ab
+ T cells are significantly increased in male
Table 3. Genes regulated in heterozygous C3.Dll1
tm1Gos/+ animals when compared to wild-type littermates.
Gene symbol Entrez ID Name Function Mean log2 ratio
Genes regulated in the liver
Cdk2 12566 Cyclin-dependent kinase 2 Regulation of cell cycle 22.24
Cth 107869 Cystathionase Methionine metabolism 22.10
Idi1 319554 Isopentenyl-diphosphate delta isomerase Cholestrol biosynthesis 21.93
Serpina3k 20714 Serine peptidase inhibitor, clade A, member 3K Peptidase inhibitor 21.89
Cul2 71745 Cullin 2 E3 ubiquitin ligase complex 21.88
Serpina3c 16625 Serine peptidase inhibitor, clade A, member 3C Peptidase inhibitor 21.87
Bhmt 12116 Betaine-homocysteine methyltransferase Methionine metabolism 21.87
Armet 74840 Arginine-rich, mutated in early stage tumors Unknown 21.82
Serpina3h 546546 Serine peptidase inhibitor, clade A, member 3H Peptidase inhibitor 21.84
Siah1a 20437 Seven in absentia 1A E3 ubiquitin ligase complex 21.84
Cyp2f2 13107 Cytochrome P450, family 2, subfamily f, polypeptide 2 Metabolism of xenobiotics 21.82
Hmgcs1 208715 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 Cholesterol biosynthesis 21.71
Cyp2c70 226105 Cytochrome P450, family 2c, polypeptide 70 Metabolism of xenobiotics 21.70
Genes regulated in the thymus
mt-Rnr2 16S rRNA, mitochondrial Mitochrondrial RNA 22.68
2310043N10Rik 66961 Unknown 22.20
Tcrb-V13 269846 T-cell receptor beta, variable 13 T cell development 22.11
Bcl11b 58208 B-cell leukemia/lymphoma 11B T cell development 22.91
Vldlr 22359 Very low density lipoprotein receptor Cholesterol metabolism 22.90
Sfrs5 Splicing factor, arginine/serine-rich 5 RNA metabolic process 21.69
Ddx6 13209 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 RNA metabolic process 21.63
Higd1b 75689 HIG1 domain family, member 1B Unknown 21.67
AK160221 AK160221 Unknown 21.62
Apc 11789 Adenomatosis polyposis coli T-cell development 21.61
Trip12 14897 Thyroid hormone receptor interactor 12 E3 ubiquitin ligase complex 21.52
EU433307 Unknown 21.50
Akap8 56399 A kinase (PRKA) anchor protein 8 Unknown 21.49
Ywhab 54401 Tyrosine 3-monooxygenase protein, beta polypeptide T-cell development 21.49
doi:10.1371/journal.pone.0006054.t003
Figure 6. Partial protein sequence alignment of Delta and Delta-like-1 proteins. The sequence alignment was performed with ClutsalW2
[90]. The missense mutation C413Y is indicated by an arrow. The species used for these alignment are: Delta-like 1 Mm, Delta-like 1 Mus musculus
NP_031891.2; Delta-like 1 Hs, Delta-like 1 Homo sapiens NP_114452.1; Delta-like 1 Rn, Delta-like 1 Rattus norvegicus NP_005609.3; Delta Dm, Delta
Drosophila melanogaster NP_477264.1; DeltaD Dr, DeltaD Danio rerio; Delta-like 1 Xl, similar to Delta-like 1 Xenopus laevis.
doi:10.1371/journal.pone.0006054.g006
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Consistent with findings for Notch signaling in lymphocyte
development [26,27] cd-TCR
+ cell numbers were not changed
in homozygous mutants. Epigenetics has been identified as
mechanism in T-cell lineage commitment [32,33], and could
therefore explain the ambiguous variant phenotype observed here.
Nevertheless, Dll1 haploinsufficiency leads to alterations in
the expression of genes, which are clearly linked to T cell
differentiation and maturation. For example, Apc and Bcl11b are
downregulated in the thymus. Both genes are essential in
maintaining the DN3 checkpoint status, when the cell fate declines
either to be ab-o rcd-T cells [34–36]. In the DN3 stage, TCRb
allelic exclusion plays a pivotal role, which is initiated by the
pre-TCR complex and controlled by Vb gene rearrangements.
Another gene of the Vb cluster, Tcrb-V13, which is required for
efficient Vb gene rearrangements [37], was also downregulated.
Additionally, two further genes, CD8a and Ywhab, which are
associated with T cell differentiation processes [38,39], were found
to be downregulated in Dll1 haploinsufficient animals.
The blood profile showed reduced CD4
+ T-cell levels in
heterozygous animals, which are significantly decreased only in
females. Although a role for Notch signaling in CD8
+-T versus
CD4
+-T commitment is already described [27], the specific role
for Dll1 remains unclear. We found a downregulation of Trip12
gene expression in thymocytes. Trip12 is a hect-protein with
possibly E3 ubiquitin ligase function [40–42]. It is already known,
that Notch signaling is highly regulated by ubiquitinylation (for
review see [43]). Recently it was shown that double mutants of
Notch and Itch, another E3 ubiquitin ligase from the hect-family,
display severely perturbed thymocyte development [44,45]. The
kind of interaction between Trip12 and Dll1 has to be elucidated.
In summary, the blood profile and the thymus transcriptomic
data affirm an essential role for Dll1 in lymphoid cell differenti-
ation, maturation and function. Dll1 haploinsufficiency of the
whole organism induces rather a subtle phenotype and the
functionality of the Dll1
C413Y allele seems to be sufficient to
maintain a normal network function. Probably Dll1 haploinsuffi-
ciency has no immunological pathological consequences, unless
the animals are subjected to an immunological challenge. This is
in accordance with recent publication, where administration of
Delta-Fc (Delta-like 1-immunoglobulin Fc fusion protein) to the
lung had an impact on the inhibition of immunological
responsiveness, but only in sensitized and challenge animals [46].
Metabolic phenotype
Dll1 haploinsufficiency leads to lighter and smaller mice with
altered fat and lean mass ratio, higher energy uptake and
metabolized energy when normalized to body weight. Hyperac-
tivity seems not to be the reason for the higher energy expenditure.
The hyperactive phenotype of C3.Dll1
C413Y/+ and 129.Dll1
tm1Gos/+
females is probably related to a neurological phenotype that
should be investigated in detail elsewhere.
Increased blood pressure in haploinsufficient animals may be
explained by increased energy demands. Although we did not
determine the basal metabolic rate, clinical-chemical parameters
in plasma and liver transcriptomic analysis indicate that Dll1
haploinsufficiency causes alterations of the entire metabolism. The
downregulation of genes in the liver is most likely caused by
external signals since Dll1 itself is not expressed in this organ
[31,47]. Thus, the downregulated genes found must be a
consequence of signals coming from outside the liver.
Total protein levels in blood plasma were significantly reduced
in Dll1 mutants. For example, the plasma concentration of
transferrin, one of the main plasma proteins, was decreased due to
Dll1 haploinsufficiency. Interestingly, nearly all examined immu-
noglobulins were significantly reduced only in female mutants.
The reduction of total protein levels in plasma is subtle and mainly
due to the reduction of selected proteins and not caused by a liver
disease since the levels of the enzymes alanine-aminotransferase
and aspartate-aminotransferase were not altered.
Table 4. Comparison of the variant phenotypes due to the C3.Dll1
tm1Gos and C3.Dll1
C413Y alleles.
Phenotyping screen Parameters
Male C3.Dll1
tm1Gos
mutant/wt (%)
Male C3.Dll1
C413Y
mutant/wt (%)
Female C3.Dll1
tm1Gos
mutant/wt (%)
Female C3.Dll1
C413Y
mutant/wt (%)
Dysmorpho-logy Body weight (g) 219.9*** 29.0** 212.9*** 214.9***
Body length (cm) 24.0* 22.4* 23.9*** 24.3***
DEXA densitometry Bone mineral density (mg/cm
2) 29.9*** 29.7** 24.5* 28.2**
Bone mineral content (mg) 214.9
n.s. 212.9
n.s. 214.0** 225.3*
Fat mass (g) 237.1* 231.8* 215.3
n.s. 252.2**
Lean mass (g) 212.8* 5.8
n.s. 212.7*** 29.8*
Neurology Locomotor acitivity (squares) 214.9
n.s. 45.8
n.s. 210.2
n.s. 75.0
*
Metabolism Food consumption (g/day) 27.0** 2.2
n.s. 222.5** 0
n.s.
Metabolized energy (kJ/g6day) 22.8*** 12.9*** 6.6
n.s. 17.8***
Cardiovascular Systolic pressure (mmHg) 10.8** 6.0
n.s.5 . 2
n.s. 10.9*
Diastolic pressure (mmHg) 10.8* 7.2
n.s. 6.0
n.s. 12.4*
Mean arterial pressure (mmHg) 10.8* 6.8
n.s. 5.7
n.s. 12.0*
Pulse (bpm) 22.4
n.s. 22.0
n.s. 27.6* 21.2
n.s.
Clinical chemistry Urea (mg/dl) 211.2** 9.1** 21.5
n.s. 15.3***
Cholesterol (mg/dl) 216.2*** 28.8* 24.6 24.7
n.s.
Triglyceride (mg/dl) 223.4** 235* 221.1* 24.4
n.s.
%: Difference of the means between mutant animals and wild-type in percent. *,**,*** indicates when in the statistical analysis the means were found to be significantly
different with a probability of *,0.05. **,0.01 and ***,0.001,
n.s. equals means not statistically significantly different.
doi:10.1371/journal.pone.0006054.t004
Dll1 Haploinsufficiency
PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e6054The transcriptional levels of cystathionase (Cth) and betaine-
homocysteine methlytransferase (Bhmt), two enzymes involved in
amino acid metabolism, were altered. Cth catalyzes one step in the
reactions from homocysteine to cysteine; Bhmt creates methionine
from homocysteine. Alterations in the function of both enzymes
have been described to alter homocysteine levels [48–50]. We
hypothesize that a reduction in these transcript levels leads to a
reduction of homocysteine levels in plasma rather than to an
altered protein metabolism. Consistent with reports on the
influence of altered homocysteine levels on bone stability [51,52]
we found a reduced bone mineral density in Dll1 haploinsufficient
animals. Recently it was reported that homocysteine is able to
modulate Notch1 function by interacting with cystein bonds in the
Notch receptor [50]. Since the Delta-like 1 does not possess
cysteine-rich regions the link between the Notch ligand and
homocysteine might be indirect.
Dll1 haploinsufficiency alters also the lipid metabolism. For
example, triglycerides and cholesterol are decreased in plasma of
Dll1
tm1Gos/+ animals. Reduced triglycerides may indicate subtle
alterations in lipid handling. Cyp2c70, downregulated in the liver of
Dll1 mutants, is involved in linolenic and arachidonic acid
metabolism. Of more interest is the downregulation of Idi1 and
Hmgcs1, two genes which encode for enzymes involved in
cholesterol biosynthesis [53,54]. Interestingly, low levels of
cholesterol leads to high expression of Adam10, coding for a
protease also known as Kuzbanian, which is essential for Notch
activation [55]. Moreover, when Adam10 is not expressed Dll1 is
overexpressed [56]. Recently, it has been shown that cholesterol is
a modulator of c-secretase activity, and therefore modulates Notch
signaling as well [57]. Our results suggest a reciprocal regulation.
A decrease in Dll1 gene expression leads to low cholesterol levels
via transcriptional regulation.
Previously, we presented six lines out of our modifier screen
with either high cholesterol or transferrin or total protein levels or
with altered T- and B-cell patterns, that were all linked to Dll1
haploinsufficiency [14]. Further studies on these lines will lead to
the discovery of several Notch-signaling suppressors.
Skeletal phenotype
Dll1 haploinsufficiency leads to a reduction in femoral and
whole-body bone mineral density as well as bone mineral content.
The role of Notch-signaling pathway components in bone
remodeling is known [58]. A close relationship between body
weight and bone mass was reported for humans. It was also shown
that bone mineral density correlates with metabolic rate and that
there is a close connection between lean mass and bone mineral
density [59–64]. Recent studies in mice demonstrate a reciprocal
hormonal link between energy metabolism and bone remodeling
[65,66]. In conclusion, the reduced bone mineral density and bone
mineral content in Dll1 mutants is most probably caused by a
reduced body size and an altered metabolic rate.
Cordes et al. reported about homeotic transformations with
incomplete penetrance in the cervical region of heterozygous Dll1
mutants [67]. Here we did not observe any alterations in the
number of vertebrae linked to Dll1 haploinsufficiency, due to the
small number of animals studied.
EGF-repeat dependent phenotype
The exchange of an amino acid in the 6
th EGF-repeat of the
Delta-like 1 protein (C413Y) leads to a phenotype that is, except
for alterations in the B- and T-cell patterns, almost identical to the
complete loss of an entire Dll1 allele. The fact that at least a few
homozygous C3.Dll1
C413Y/C413Y mutants were born suggests
variable doses of functional Delta-like 1 protein.
Proteolysis mediated Notch signaling regulation
The Notch signaling pathway is mediated by proteolysis and
does not seem to be mediated by second messengers (for review see
[2]). But some questions remain open. So it is still unclear which
E3 ubiquitin ligase monoubiquitinates Notch prior to c-secretase
cleavage [3]. We have already mentioned that Dll1 haploinsuffi-
ciency leads in the thymus to downregulation of a protein that
shows E3 ubiquitin ligase function, Trip12. However, this is not the
only gene found to be downregulated that belongs to the ubiquitin
machinery. For example, Siah1, which belongs to the E3 ubiquitin
ligase complex, is known to promote degradation of Numb, and
thereby leads to activation of Notch [68–71]. Cul2, another
protein of the E3 ubiquitin ligase complex, degrades HIF-1a,
whose interaction with NICD leads to transcriptional activation of
Notch targets [72–74]. As Notch signaling is fine-tuned by
different proteases, it can be regulated also by proteases inhibitors.
Here we found that due to Dll1 haploinsufficiency three of the 14
components of the human SERPINA3 (a1-antichymotrypsin)
homolog cluster were downregulated, Serpina3c, Serpina3h and
Serpina3k. Other components of the cluster were not found to be
differentially regulated, like Serpina3a and Serpina3g. Serpina3h and
Serpina3k probably encode protease inhibitors, whereas Serpina3c is
more likely an ortholog of kallistatin in humans [75]. Kallistatin is
known to have an influence on blood pressure [76,77].
Taken together, Dll1 haploinsufficiency leads to a downregula-
tion of selected genes that could function as modulators of the
Notch signaling pathway, probably due to feedback mechanisms
in maintaining the fine-tuning of this signaling network.
Link to Wnt signaling
Interactions between Notch and Wnt signaling were first
uncovered in the developing wing disc of the fly (for review see
[78]). In vertebrates, mutually dependent interactions between
Notch and Wnt signaling have been described in several processes
like somitogenesis or T-cell development [26,78]. Wnt signaling
activates usually the expression of Notch ligands. The recurrence
of this regulatory relationship is higher than the occurrence of
regulation in two distinct interacting networks, suggesting that
probably Wnt and Notch signaling devices are part of an
integrative system called ‘Wntch’ [78]. It is not the aim of this
study to investigate this hypothesis. Nevertheless, we detected in
this work a relation between the Notch signaling and the Wnt
signaling pathway. The two genes, Apc and Siah1, which were
found to be downregulated in Dll1 mutants, are known to act via
b-catenin and by extension on Wnt signaling [34,35,70].
Conclusion
Dll1 haploinsufficiency leads to a complex phenotype with
several biological processes altered. These alterations emphasize
the importance of Dll1 mainly in metabolism, energy balance and
in immunology. The Dll1 haploinsufficient animals are smaller,
lighter, with altered fat to lean ratio and have an increased blood
pressure and a slight bradycardia. At the immunological level a
subtle phenotype is observed due to the effects and fine-tuning of
the signaling network at different levels of differentiation,
proliferation and function of lymphocytes. Moreover, the
importance of the proteolytic regulation of the Notch signaling
network is emphasized.
Materials and Methods
Mice
Mice were housed and handled according to the federal animal
welfare guidelines and all the animal studies were approved by the
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continuously controlled specific pathogen-free (SPF) hygiene
standard according to the Federation of European Laboratory
Animal Science Associations (FELASA). For this study we used
mice carrying the Dll1
tm1Gos allele on a 129X1/SvJ background
[15], and these mice were outcrossed 11 generations to wild-type
C3HeB/FeJ mice. The mutant line was further maintained by
mating between siblings. The C3.Dll1
C413Y/+ mutant line was
isolated from an ENU mutagenized combined sperm and genome
archive by sequencing the Dll1 coding region [29]. Phenotypic
screening was performed by comparing heterozygous mice with
the same number of age- and sex-matched littermate controls [20].
Mice were genotyped for the Dll1-LacZ insertion as described
elsewhere [14]. The isogenicity of the Dll1
tm1Gos in the C3HeB/FeJ
background was evaluated with the SNP panel developed at our
institute for linkage analysis as described elsewhere [14].
Metabolic screen
At the age of 17 to 19-weeks wild-type and heterozygous
Dll1
tm1Gos mutants entered the metabolic screen in the GMC, and
were analyzed as described previously [79–81]. In the primary
screen mice were single-caged and fed ad libitum for a period of 14
days. The following parameters were measured: body weight, food
consumption (Fcon), rectal temperature (Tre), daily faeces produc-
tion (Fec), energy uptake (Eup), energy content of the faeces (Efec),
metabolizable energy (Emet) and food assimilation coefficient (Fass).
In the tertiary screen the body composition was analyzed. At a
mean of 31 weeks of age the animals were killed, weighed and the
gastrointestinal tract was removed. Body composition was
determined by drying the dissected carcass, weighing the dry
carcasses and fat mass was determined by extracting the lipids
using a refluxing Soxhlet apparatus with petrol ether as solvent for
16 hours [82]. The post extraction dry mass was determined. Lean
mass was calculated as the carcass weight minus the fat mass.
Cardiovascular screen
At the age of 14 weeks the mice entered the cardiovascular
screen of the GMC [83]. Blood pressure was measured in
conscious mice with a non-invasive tail-cuff method using the
MC4000 Blood pressure Analysis Systems (Hateras Instruments
Inc.). Pulse detection, cuff inflation and pressure evaluation were
automated by the system software. At least 20 to 48 individual
measurements were pooled to obtain a mean over the four
measurements days for each animal. The electrocardiogram
analysis (ECG) was performed in isoflurane-anesthetized mice by
the use of three metal bracelets on the joints of the feet. Positioning
on the front paws and the left hind-paw allows the recording of the
bipolar standard limbs I, II, and III and the augmented unipolar
leads AVF, AVR and AVL. The ECG was recorded for seven
minutes. In the quantitative ECG analysis sets of 5 analyzed beats
were averaged for each animal. The shape analysis of the ECG
traces was performed with the software ECG-auto (EMKA
technologies).
Clinical chemistry screen
Blood samples were obtained from 12-week-old mice by
puncturing the retro-orbital sinus under anesthesia [84]. Plasma
was separated by centrifugation (10 min, 46566g; Biofuge,
Heraeus; Hanau, Germany) diluted 1:2 with deionized water
and analyzed in the GMC for clinical chemistry parameters. The
20 parameters measured cover a broad spectrum suitable to
investigate alterations in metabolism, organ function and electro-
lyte homeostasis. In detail the electrolytes sodium, potassium, total
calcium, chloride and inorganic phosphorus; total protein in
plasma and the proteins ferritin and transferrin; the metabolites
creatinine, urea, uric acid, cholesterol, triglycerides and glucose;
and the enzymes creatine kinase, alanine-aminotransferase (ALT),
aspartate-aminotransferase (AST), alkaline phosphatase, a-Amy-
lase and lipase were analyzed. The parameters were analyzed
using an Olympus AU 400 autoanalyzer and adapted reagents
from Olympus (Hamburg, Germany), as described elsewhere [85].
The results presented here include individuals investigated under
the same analytical conditions.
Immunology screen
A fraction of the blood sample taken at 12 weeks of age was
separated to analyze immunological parameters using ELISA and
flow cytometry, as described previously [86]. The following main
cell populations were analyzed by flow cytometry: B cells (CD19
+
clone 1D3), B1 B cells (CD19
+CD5
+, clone 53-7.3), B2 B cells
(CD19
+CD5
2), T cells (CD3
+, clone 145-2C11), CD4
+ T cells
(clone RM4-5), CD8
+ T cells (CD8a, clone 53-6.7; CD8b, clone
H35-17.2), c/dT cells (clone GL3), granulocytes (Gr-1
+, clone
RB6-8C5), and NK cells (CD49b
+, clone DX5). Data were
acquired on a LSR II flow cytometer (Becton Dickinson, USA)
and were analyzed using FlowJo software (TreeStar Inc, USA). All
samples were acquired until a total number of 30,000 cells were
reached.
The plasma levels of IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA
were determined simultaneously in the same sample using a bead-
based assay with monoclonal anti-mouse antibodies conjugated to
beads of different color regions (Biorad, USA), and acquired on a
Bioplex reader (Biorad). The presence of rheumatoid factor and
anti-DNA antibodies was evaluated by indirect ELISA with rabbit
IgG (Sigma-Aldrich, Steinheim, Germany) and calf thymus DNA
(Sigma-Aldrich), respectively, as antigens and AP-conjugated goat
anti-mouse secondary antibody (Sigma-Aldrich). Serum samples
from MRL/MpJ-Tnfrsf6
lpr mice (Jackson Laboratory, Bar Har-
bor, USA) were used as positive controls in the autoantibody
assays.
Dysmorphology screen
The animals were checked for general condition and health at
the age of 5 weeks when entering the GMC. At the age of nine
weeks mice were subjected to morphological observation following
the protocol described previously [87]. Growth, weight, body size,
eye, coat hair growth, coat hair texture, hair follicle structure and
orientation, skin pigmentation, skin texture and condition of
vibrissae, limbs, digits, tail, teeth, ear morphology, musculature,
seizures and epilepsy, motor capabilities and coordination,
movement, feeding and drinking behavior, respiratory system,
reproductive system or other abnormalities in the body morpho-
logy were investigated. X-ray analysis, as well as DEXA scans were
performed at the age of 16 weeks. For the X-ray analysis animals
were analyzed with the Faxitron X-ray Model MX-20 (Specimen
Radiography System, USA). To check bone density alterations the
mice were investigated with the pDEXA Sabre X-ray Bone
Densitometer (Norland Medical Systems. Inc., UK).
Molecular phenotyping
At the age of 16 weeks five wild-type and five heterozygous
Dll1
tm1Gos/+ mutants were killed between 9 and 12 am by carbon
dioxide and gene expression in liver, spleen, thymus and brain was
analyzed as described previously [24]. Briefly, RNA was extracted
using the RNeasy Midi kit (Quiagen) following the manufacturer’s
instructions. For each cDNA array, 15 mg of total RNA were used
for reverse transcription and indirect labeled with the fluorescent
dyes. Cy3 or Cy5 (Amersham Biosciences, Freiburg, Germany),
Dll1 Haploinsufficiency
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e6054according to a modified TIGR protocol [88]. In total our cDNA
chips contains 20355 spotted sequences (for a full description see
GEO database GPL3697). All experiments were submitted to the
GEO database: GSE11867. After hybridization the dried slides
were scanned with a GenePix 4000A microarray scanner, and the
images were analyzed using the GenePix Pro 6.0 image processing
software (Axon Instruments). Statistical analyses were performed
using TM4 microarray suite [24,89].
Data analysis
For biological interpretation of the data the software tools
MetaCore
TM (GeneGo Inc., St. Joseph, MI, USA) and Biblio-
Sphere PathwayEdition
TM Genomatix Software GmbH, Munich,
Germany) were used. The databases Mouse Genome Informatics
(MGI, The Jackson Laboratory, USA), MapViewer (NCBI, USA),
GeneCardsH (Weizmann Institute of Science, Israel), The Kyoto
Encyclopedia of Genes and Genomes (KEGG, Kanehisa Labo-
ratories, Japan) and The Comprehensive Enzyme Information
System (BRENDA, TU Braunschweig, Germany) were used to
further interpret the biological meaning of the data.
Statistical analyses
All statistical tests were performed using either the software
package GraphPad Prism 4.01 (GraphPad Software, USA) or the
R Version 2.7.0 for Windows provided by the R Foundation of
Statistical Computing. Outliers defined as those falling outside the
25
th or 75
th quantile and 1.5 times the interquantile range were
discarded. The distribution of the data was assessed using the
Shapiro-Wilk normality test. The variances were compared using
the Levene Test. Samples with continuous data were compared
using the two-sample unpaired t-test or the Mann-Whitney test.
Samples with categorical data where compared using the Fisher’s
Exact Test or the Chi-square Test.
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